Answers are grounded in this paper and cite their sources.
Introduction Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is estimated to affect upto 70–80% of people with type 2 diabetes mellitus (T2DM). Although several anti-hyperglycemic drugs have shown to be effective in such patients, there remain an unmet need for newer drugs. The objective of this meta-analysis was to analyze the effect of ipragliflozin on aspartate aminotransferase (AST), alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT) levels in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Parveen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: